Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Healios KK ( (JP:4593) ) has issued an update.
Healios KK announced its development policy for HLCM051, prioritizing its use as a treatment for ARDS. The company plans to initiate a global Phase 3 study in early 2026, with patient enrollment starting in Japan and expanding to the United States. While discussions continue for the ischemic stroke treatment under the SAKIGAKE Designation System, the application will not proceed in a rolling submission format by early 2026. This development strategy is not expected to impact the company’s financial results for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios KK operates in the biotechnology industry, focusing on regenerative medicine and cell therapy. The company is primarily involved in developing treatments for acute respiratory distress syndrome (ARDS) and ischemic stroke, with a market focus on innovative medical solutions.
Average Trading Volume: 2,275,879
Technical Sentiment Signal: Sell
Current Market Cap: Yen49.07B
For a thorough assessment of 4593 stock, go to TipRanks’ Stock Analysis page.